SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: floWteiuQ who wrote (4413)10/21/2016 9:55:53 AM
From: GregorioAllegri  Read Replies (2) | Respond to of 4474
 
Eventually, there will be price controls on all aspects of medicine in the USA, just as in the rest of the developed world. Sanders and Cummings are just at the leading edge of this. The 1000% increase (in real dollars) in health care and higher education since 1970 are not sustainable, if the US is to remain competitive with the rest of the world, and its citizens are to have access to medicine and a college education. There are many other forces of change in the world that will make this so. The alternative, eventually, is a world inhabited by a few owners and a multitude of beggars. This change in the way we fund healthcare will require only the retirement of the laissez-faire free market disciples of Ayn Rand (e.g. the greed is good crowd) in congress by the voters. Sanders is going to hammer this one for the good of the country.

Pity they picked on a small, money losing company whose drugs, one and all, are life savers for people with the mutations only controlled by their internally discovered drugs. Probably, the money Ariad spends on defending themselves will come out of research into new anti-cancer medicines. But, $199k is not an affordable price, I think everyone will agree, no matter how much Ariad needs the money (and I hate to have my shares diluted.)

Go brigatinib!

Sold half my newish shares when I got a double in the twelves. Will buy them back if we go down to a price where I think I can get another double.

GA